61 Y Combinator companies in Drug Discovery and Delivery, with team size, growth, open roles and funding.
Updated weekly, last on November 9, 2026. Roster from Y Combinator's public directory.
| Company | Batch | Team | 6 mo | 12 mo | Open roles | Total raised | Last round |
|---|---|---|---|---|---|---|---|
Unleash the potential of genomic medicine using AI | W22 | 56 | +8% | +22% | 0 | $36.5M | Series B$26M, Oct 2026 |
Medicinal Chemistry powered by Machine Learning | W20 | 41 | −5% | −9% | 1 | $26.4M | Grant$24M, May 2022 |
We're building fully automated labs for protein engineering | S21 | 40 | +29% | +43% | YC | $50.9M | Series A$40M, Aug 2026 |
Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company… | S20 | 37 | +3% | +3% | 0 | $143M | Series A$60M, Mar 2026 |
Developing long-lasting drug formulations 50% faster | W23 | 35 | −5% | −5% | 0 | $16.5M | Series A$12M, Mar 2025 |
We make injections as easy as pushing a button! | S21 | 31 | +15% | +29% | YC | ||
We use AI to design antibodies for intractable diseases | S20 | 28 | +22% | +40% | 1 | $37.4M | Series A$26M, May 2024 |
We use human data and AI to develop better drugs faster. | S15 | 26 | −4% | −21% | 2 | $134M | Series C$98M, Oct 2024 |
Targeting Cancer with Click Chemistry | W15 | 26 | −10% | −7% | 0 | $65.4M | Grant$1.9M, Dec 2021 |
We create activating antibodies to treat diseases others can’t. | W20 | 25 | +4% | +14% | 0 | $12.9M | Seed$7.6M, May 2024 |
The next generation of induced-proximity medicines. | W20 | 25 | +14% | +14% | YC | $16M | Undisclosed round$16M, May 2026 |
Discovering drugs that target the DNA regulome | S21 | 24 | −8% | −8% | 0 | $27.8M | Seed$11.2M, Sep 2026 |
Programmable biology company for psychoactive effect design | S21 | 23 | −4% | −4% | 0 | $24.3M | Seed$12.7M, Feb 2025 |
Using the immune system to cure disease | S21 | 22 | −31% | −49% | 7 | $25.6M | Series A$21M, Jun 2025 |
Creating new protein-based drugs at scale | W23 | 21 | −9% | −16% | 0 | $500K | Seed$500K, Feb 2025 |
Discovering the true signals of disease to power life-changing drugs. | S19 | 21 | +5% | +17% | 0 | Undisclosed roundMay 2021 | |
Using CRISPR to find treatments for cancer and inflammation | W20 | 20 | +18% | +33% | 1 | $21.4M | Series A$12.5M, Aug 2026 |
Menten AI designs peptide and protein therapeutics using quantum… | W20 | 19 | 0% | +6% | 0 | $4M | Seed$3.6M, May 2023 |
Next-generation mRNA platform to solve cancer, COVID and climate. | W17 | 15 | 0% | −12% | 0 | $60M | Series A$231K, Apr 2024 |
Artificial intelligence for drug discovery. | W15 | 15 | −12% | −6% | 0 | ||
Perlara: building the YC for rare disease parents | W16 | 14 | 0% | −7% | 0 | ||
The world's first AI-maximalist pharma company | S25 | 13 | 0 | $500K | YC investment$500K, Sep 2025 | ||
The dynamic single-cell analysis company | S21 | 13 | 0% | −7% | 0 | $5.1M | Grant$200K, Aug 2025 |
Empowering every doctor and every patient to participate in research | W23 | 12 | +50% | +50% | 0 | $1M | Seed$1M, Apr 2023 |
Arpeggio Bio develops drugs targeting transcription factors using AI… | S19 | 11 | −31% | −8% | 0 | ||
Combination therapeutics for the world's toughest diseases | S23 | 10 | +11% | +11% | 0 | $8.7M | Seed$4.5M, Mar 2025 |
Adventris makes cancer vaccines | W23 | 10 | +43% | +25% | 0 | $500K | YC investment$500K, Jan 2024 |
Generative AI for protein design | W23 | 9 | −18% | −10% | YC | $500K | Seed$500K, Sep 2026 |
Delivering RNA therapies. | W18 | 8 | −11% | −27% | 0 | $10.6M | Grant$8.3M, Dec 2021 |
Agentic platform for predictive neuro drug discovery + data foundry. | W25 | 7 | 0% | 0 | $500K | Non-equity support$500K, Jul 2026 | |
Deliver genes to any cell with AI | S23 | 7 | 0% | +17% | 0 | $500K | YC investment$500K, Sep 2023 |
Skin patches for generic drug delivery. | W18 | 7 | −36% | −36% | 0 | $2.2M | Undisclosed round$2.2M, Jan 2021 |
The agentic drug company. We simulate human biology. | W26 | 6 | YC | $500K | YC investment$500K, Apr 2026 | ||
Evolutionary intelligence for autoimmune disease | W26 | 6 | 0 | $500K | YC investment$500K, Feb 2026 | ||
Your biopharma team, from molecule design to portfolio strategy | S22 | 6 | +20% | +20% | 0 | Pre-seedAug 2022 | |
Developing milk-inspired therapeutics for infectious diseases | S21 | 6 | 0% | 0% | 0 | $130K | Seed$5K, Jan 2024 |
The foundation for the next era of science | S21 | 6 | +20% | +20% | 2 | SeedJan 2023 | |
Enabling T cell immunotherapy discovery, development and manufacturing | W17 | 6 | +20% | 0 | $5.1M | Non-equity support$365K, Jun 2023 | |
AI-native pharma company | S26 | 5 | 0 | $500K | YC investment$500K, Jul 2026 | ||
The Intelligence layer for Drug Manufacturing | X26 | 5 | 0% | 0% | 0 | ||
AI and Data for Cancer Therapeutics | W26 | 5 | −17% | YC | $500K | YC investment$500K, Mar 2026 | |
Multi-targeted therapeutics to treat complex diseases | S21 | 5 | −17% | −29% | 0 | $8M | Grant$8M, Aug 2025 |
Curing cancer. Starting with dogs. | S26 | 4 | 0 | $4.5M | Seed$4M, Aug 2026 | ||
Multimodal foundation models to predict uncollected patient biology | W26 | 4 | 0 | ||||
Exonic is an AI-native cell and gene therapeutics company. | F25 | 4 | YC | $500K | YC investment$500K, Sep 2025 | ||
Gen AI molecular simulations that reproduce wetlab results | S24 | 4 | −20% | 0 | $500K | YC investment$500K, Sep 2024 | |
Making hard molecules for Pharma and Biotech | S25 | 3 | YC | $500K | YC investment$500K, Sep 2025 | ||
Converting biology into digital molecular maps | S24 | 3 | 0 | $500K | YC investment$500K, Sep 2024 | ||
Growing micro-organs to find new drugs | W22 | 3 | 0 | Pre-seedMar 2022 | |||
Computational antibody design | W18 | 3 | 0 | $1.5M | YC investment$120K, Jan 2018 |
Every launched company in YC's public directory, with its batch, status, industry and location. New companies show up the week YC lists them.
Each company is matched to Crustdata by its website. Crustdata adds team size and its change over 6 and 12 months, open roles from job postings, reported funding, and founders' past employers.
Hiring the most counts distinct roles posted in the last 60 days. Growth needs 10+ people today, shrinking 20+ a year ago, so tiny teams do not top the lists. Rebuilt every week.
The numbers on this page come from three Crustdata API calls. Crustdata tags 5,000+ companies with Y Combinator as an investor; swap the filter for any investor, industry or headcount range and track your own list, with founders' work emails one call away.
# 1. every company with Y Combinator as an investor curl https://api.crustdata.com/company/search \ -H "authorization: Bearer $CRUSTDATA_API_KEY" \ -H "x-api-version: 2025-11-01" \ -d '{ "filters": { "field": "funding.investors", "type": "in", "value": ["Y Combinator"] }, "fields": ["basic_info.name", "headcount.total", "headcount.growth_percent", "funding.total_investment_usd"], "limit": 100 }' # 2. open listings per company, last 60 days (limit 0 = counts only) curl https://api.crustdata.com/job/search \ -H "authorization: Bearer $CRUSTDATA_API_KEY" \ -H "x-api-version: 2025-11-01" \ -d '{ "filters": { "op": "and", "conditions": [ { "field": "company.basic_info.company_id", "type": "in", "value": [...] }, { "field": "metadata.date_added", "type": "=>", "value": "2026-08-24" } ]}, "limit": 0, "aggregations": [{ "type": "group_by", "field": "company.basic_info.company_id", "agg": "count" }] }' # 3. the same company filter as a weekly watch: POST /watch/company/search
61 Y Combinator companies are in Drug Discovery and Delivery; 54 are active.
6 companies posted roles in the last 60 days, led by Parallel Bio (7 roles), Verge Genomics (2 roles) and Output Labs (2 roles). 12 mark themselves as hiring on YC's directory.
By team growth over 6 months (10+ people): Novelcare (+50%), Adventris Pharmaceuticals (+43%) and Adaptyv (+29%).
Largest latest rounds in the last 12 months, after their YC batch: Gilgamesh Pharmaceuticals ($60M), Adaptyv ($40M) and WhiteLab Genomics ($26M).